Neurology Minute
American Academy of Neurology
The Neurology Minute podcast delivers a brief daily summary of what you need to know in the field of neurology, the latest science focused on the brain, and timely topics explored by leading neurologists and neuroscientists. From the American Academy of Neurology and hosted by Stacey Clardy, MD, Ph.D., FAAN, with contributions by experts from the Neurology journals, Neurology Today, Continuum, and more.
Episodes
Mentioned books
Nov 20, 2025 • 4min
Outcomes After RCVS With Convexity Subarachnoid Hemorrhage
Dr. Dan Ackerman and Dr. Isabel Hostettler discuss the diagnosis, risk factors, and prognosis of RCVS, highlighting the need to recognize symptoms and distinguish it from other causes of subarachnoid hemorrhage. Show reference: Hostettler IC, Ponciano A, Wilson D, et al. Outcomes After Reversible Cerebral Vasoconstriction Syndrome With Convexity Subarachnoid Hemorrhage: Individual Patient Data Analysis. Neurology. 2025;105(5):e213984. doi:10.1212/WNL.0000000000213984
Nov 19, 2025 • 4min
November President Spotlight: Medicare 2026 Rulemaking
In the November episode of the President's Spotlight, Dr. Jason Crowell talks with Dr. Natalia Rost about the Centers for Medicare & Medicaid Services final rule for how physicians are reimbursed in 2026. Show reference: https://www.aan.com/about-the-aan/presidents-spotlight
Nov 18, 2025 • 3min
Safety and Efficacy of Nipocalimab in Adults With Generalized Myasthenia Gravis (Vivacity-MG3)
Dr. Aaron Zelikovich discusses a recent article on nipocalimab and its role in treating generalized myasthenia gravis. Show citations: Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105-116. doi:10.1016/S1474-4422(24)00498-8
Nov 17, 2025 • 2min
Interpreting Cerebrospinal Fluid in the 2024 McDonald Criteria Revisions
Dr. Katherine Havard Coiro discusses the 2024 McDonald Criteria for Multiple Sclerosis and how to interpret cerebrospinal fluid. Show reference: Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Montalban, Xavier, et al. The Lancet Neurology, Volume 24, Issue 10, 850 - 865
Nov 14, 2025 • 4min
Women History Minute - Marcelle Lapicque
In this episode of the Neurology Minute, Dr. Alison Christy delves into another women's history minute to discuss Marcelle Lapicque.
Nov 13, 2025 • 5min
Super Refractory Status Epilepticus Diagnosis, Management, and Prognostication
Dr. Alison Christy and Dr. Matthew Ryan Woodward discuss the complexities of status epilepticus, focusing on its definitions, the transition to refractory and super-refractory states, and the implications for treatment. Show citation: Woodward MR, Brown JP, Kittner SJ, et al. Super-Refractory Status Epilepticus Diagnosis, Management, and Prognostication: An International Survey Study. Neurol Clin Pract. 2025;15(5):e200520. doi:10.1212/CPJ.0000000000200520
Nov 12, 2025 • 3min
Prodromal Phase of Migraine - Part 2
In the second part of this two-part series, Dr. Bradley Ong explains the four clinical phases of a typical migraine attack. Show citation: Lipton RB, Stokes J, Evans CJ, et al. Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing. Headache. 2025;65(8):1355-1368. doi:10.1111/head.15024
Nov 11, 2025 • 3min
Prodromal Phase of Migraine - Part 1
In part one of this two-part series, Dr. Bradley Ong discusses the prodrome phase of migraine and how it represents the earliest stage of the attack. Show citation: Lipton RB, Stokes J, Evans CJ, et al. Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing. Headache. 2025;65(8):1355-1368. doi:10.1111/head.15024
Nov 10, 2025 • 2min
Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 2
In part two of this series, Dr. Stacey Clardy and Dr. Sandra Vukusic discuss gender disparities in the treatment of multiple sclerosis. Show citation: Gavoille A, Leray E, Marignier R, et al. Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis. Neurology. 105(4) e213907. doi:10.1212/WNL.0000000000213907
Nov 7, 2025 • 4min
Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 1
In part one of this two-part series, Dr. Stacey Clardy and Dr. Sandra Vukusic discuss what disease-modifying therapies can be safely continued and strategically timed when pregnancy is anticipated. Show citation: Gavoille A, Leray E, Marignier R, et al. Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis. Neurology. 105(4) e213907. doi:10.1212/WNL.0000000000213907


